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Abstract
Background: HIV-1 remains sequestered during antiretroviral therapy (ART) and can resume high-level replication upon
cessation of ART or development of drug resistance. Reactivity of memory CD8+ T lymphocytes to HIV-1 could
potentially inhibit this residual viral replication, but is largely muted by ART in relation to suppression of viral antigen
burden. Dendritic cells (DC) are important for MHC class I processing and presentation of peptide epitopes to memory
CD8+ T cells, and could potentially be targeted to activate memory CD8+ T cells to a broad array of HIV-1 epitopes during
ART.
Principal Findings: We show for the first time that HIV-1 peptide-loaded, CD40L-matured DC from HIV-1 infected persons
on ART induce IFN gamma production by CD8+ T cells specific for a much broader range and magnitude of Gag and Nef
epitopes than do peptides without DC. The DC also reveal novel, MHC class I restricted, Gag and Nef epitopes that are able
to induce polyfunctional T cells producing various combinations of IFN gamma, interleukin 2, tumor necrosis factor alpha,
macrophage inhibitory protein 1 beta and the cytotoxic de-granulation molecule CD107a.
Significance: There is an underlying, broad antigenic spectrum of anti-HIV-1, memory CD8+ T cell reactivity in persons on
ART that is revealed by DC. This supports the use of DC-based immunotherapy for HIV-1 infection.
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Introduction
The breadth of CD8+ T cell reactivity specific for HIV-1
antigens is considered a key factor in host control of HIV-1
infection [1]. Production of interferon c (IFNc) by memory CD8+
T cells that are specific for a broad array of HIV-1 epitopes,
especially those within the Gag protein, is associated with slower
HIV-1 disease progression [2,3]. Control of HIV-1 infection has
also been linked to polyfunctional reactivity of memory CD8+ T
cells, i.e., T cells that produce more than one immune mediator in
response to HIV-1 antigens [4], particularly Gag [5,6,7,8]. This
has led to the concept that effective prophylactic and immuno-
therapeutic vaccines for HIV-1 will need to induce a broad, HIV-1
antigenic spectrum of CD8+ T cell reactivity.
Induction of broad and robust T cell reactivity could be
particularly important in immunotherapy of HIV-1 infection
during antiretroviral therapy (ART) [9]. However, virus-suppres-
sive ART results in a contraction of anti-HIV-1, CD8+ memory T
cell function related to the lower HIV-1 antigenic burden
[10,11,12,13]. Based on recent evidence that dendritic cells (DC)
are important for activation of memory CD8+ T cell reactivity to
influenza A virus, herpes simplex virus type 1 and human
cytomegalovirus [14,15,16,17,18], we hypothesized that DC could
enhance the breadth of T cell responses to HIV-1, particularly in
persons on ART. In the present study, we therefore analyzed the
breadth of memory, recall CD8+ T cell responses in vitro from
HIV-1 infected subjects on ART to DC loaded with HIV-1
peptides. Our results show that HIV-1 peptide-loaded, mature DC
induced IFNc production to a much broader range of HIV-1 Gag
and Nef epitopes than did peptides without DC. The MHC class I
restricted Gag and Nef epitopes included novel ones that could
activate polyfunctional T cells producing various combinations of
IFNc interleukin 2 (IL-2), TNFa, macrophage inhibitory protein
1b (MIP-1b) and the cytotoxic de-granulation molecule CD107a.
This indicates that there is a broader and more robust array of
memory CD8+ T cells specific for HIV-1 antigens circulating in
persons on ART than has previously been appreciated, and
supports use of DC-based immune therapies.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12936
Methods
Study subjects
This research was part of the Pittsburgh Multicenter AIDS
Cohort Study (MACS), an investigation of the natural history of
HIV infection, and was approved by the University of Pittsburgh
Institutional Review Board. 7 HIV-1 seropositive homosexual men
on ART were randomly selected for study from the Pittsburgh,
PA, portion of the MACS (Table S1). Four HIV-1 seronegative
persons were included as controls. All study subjects gave written
informed consent.
DC cultures
To obtain immature DC, CD14+ monocytes were positively
selected from peripheral blood mononuclear cells (PBMC) using anti-
CD14 monoclonal antibody (mAb)-coated magnetic microbeads
(StemCell Technologies, Vancouver, Canada) to a purity of .96%,
cultured for 5 to 6 days in AIM V medium (GIBCO, Grand Island,
NY) containing 1000 U/ml of recombinant IL-4 (R & D Systems,
Minneapolis, Minn.) and 1000 U/ml of recombinant granulocyte-
monocyte colony stimulating factor (GM-CSF) (Amgen, Seattle,
WA). Fresh IL-4 and GM-CSF were added every other day. The DC
were treated with maturation factor CD40L (0.5 mg/ml; Amgen or
Alexis, San Diego, CA) for 40 h to induce DC maturation.
The number of viable DC was determined by typical morphology
in trypan blue dye-stained preparations. The maturation status of
the DC was determined by flow cytometry as the percent positive
and mean fluorescent intensity of expression of MHC class II (HLA-
DR), MHC class I (HLA ABC), CD80, CD86 and CD83. Viable
DC displayed a characteristic DC morphology and cell surface
marker expression and responded to stimulation with CD40L.
Synthetic peptides
A library of HIV-1 peptides (consecutive 15mers overlapping by
11 amino acids) spanning the consensus B HIV-1 proteome was
obtained through the AIDS Research and Reference Reagent
Program, Division of AIDS, NIAID, NIH. These were used as
singlets or in pools of consecutive peptides. Known, ‘‘A-list’’
epitopes were identified by the Los Alamos CTL/CD8+ T Cell
Epitope Database [19]. Potential new epitopes were determined
based on HLA anchor residue motifs within protein sequences for
specified HLA alleles using the HLA Binding Motif Scanner,
which is based on two motif libraries [20,21]. HIV-1 peptides with
various N and C terminal truncations and extensions were
synthesized for determination of HLA association (SynBioSci,
Livermore, CA). Preliminary dose-response experiments were
done to determine the optimal concentration of peptides to be
used in the T cell functional assays.
ELISPOT assay
An ELISPOT assay modified from AIDS Clinical Trials Group
protocol A5181 was used to determine single cell IFNc production
[22]. Briefly, plates were pre-labeled with coating antibody (1-
D1K; 100 mL/well or 1 mg/mL solution; Mabtech, Stockholm,
Sweden), incubated overnight at 4uC, washed 4 times with PBS
and blocked with RPMI 1640 medium with 10% heat-inactivated
FCS (RPMI-10% FCS) (Gemini Bio-Products, West Sacramento,
CA) for 1 h at 37uC. After decanting the blocking medium, DC in
RPMI-10% FCS were added to the wells and loaded with peptides
(5–10 mg/ml per peptide) for 2 h at 37uC. Responder cells were
autologous PBMC or CD8+ T cells (96–98% pure) positively
selected from PBMC using anti-CD8 mAb-coated, magnetic
microbeads (StemCell). The peptide-loaded DC (stimulators) were
washed to remove excess peptide and mixed with responder cells
at a responder-to-stimulator [R:S] cell ratio of 10 to 1 and
incubated for 18 h with peptide-loaded DC at 37uC in a 5% CO2
atmosphere. The wells were washed with PBS and treated with
biotinylated anti-IFN-c mAb (1 ml/ml; 100 ml/well) and incubated
at 37uC for 3 hours. Avidin-peroxidase (100 ml/well) was added
after the biotinylated antibody was decanted and the plates were
washed four times with PBS-0.05% Tween 20 (Fisher Scientific,
Pittsburgh, PA). Diaminobenzidine solution (100 mL/well; Sigma,
St. Louis, MO) was added to each well for 5 minutes at room
temperature. The plates were washed and air-dried overnight. A
negative control (medium without peptides), and 2 positive
controls – CEF (1 mg/ml), which is a mixture of human
cytomegalovirus, Epstein-Barr virus and influenza A virus [23]
(NIH AIDS Research & Reference Reagent Program), and
staphylococcus enterotoxin B (SEB, 0.5 mg/ml; Sigma, St. Louis,
MO), were included in each assay. After the plates were processed
for staining of IFNc, the spots were counted with an ELISPOT
reader system (Cell Technology, Columbia, MD). Data were
expressed as spot-forming cells (SFC) per 106 cells. The results
were considered positive if the number of SFC in the peptide-
stimulated cultures was more than 50 and above the mean plus
two standard deviations of SFC in cultures with medium alone.
In some experiments, HLA restriction of the T cell responses
was confirmed by ELISPOT assay using a panel of EBV-
transformed B cell lines (BLCL) matched with the effector cells
at only one MHC class I allele.
Surface and intracellular staining (ICS)
Frozen-thawed PBMC were suspended to 26106/ml in RPMI-
10% FCS and rested overnight at 37uC. The PBMC were then
cultured with 2 ml each of T cell costimulatory mAb specific for
CD28 and CD49d (aCD28/49d, 1 mg/ml; BD Biosciences),
monensin (5 mg/ml; Sigma) and brefeldin A (5 mg/ml; Sigma) to
inhibit extracellular release of the immune mediator CD107a-
PECy5 (20 ml; BD PharMingen, San Diego, CA), and peptides or
peptide pools (5 mg/ml). In some experiments, DC loaded with
peptide (5 mg/ml) were used at a 1:10 ratio with PBMC but
without aCD28/49d. Negative controls (without peptides) and
positive controls (CEF, 1 mg/ml and SEB, 1 mg/ml) were included
in each assay. Cells were incubated for 6 h at 37uC and then kept
at 4uC for 16 h. The cells were washed, fixed using the Cytofix/
Cytoperm kit (BD PharMingen) and stained with mAb CD8-APC
Cy7, CD4-APC Cy7, IL-2-APC (BD Biosciences), CD3-PE Cy7,
IFNc-FITC, MIP-1b-PE (BD PharMingen) and TNFa-PB
(eBiosciences). Following staining, the cells were washed, fixed
and analyzed with an LSR II flow cytometer (BD Immunocyto-
metry Systems), with 200,000 to 1,000,000 events collected per
sample. T lymphocyte subsets were analyzed by first identifying
and gating the whole lymphocyte population according to light
scatter properties (FSC and SSC), followed by gating T cell subsets
based on the expression of the surface markers CD3 and CD8, as
well as the intracellular expression of IL-2, IFNc, TNFa, MIP-1b
and CD107a compared to negative controls. All data were
background-subtracted using the non-antigen stimulated control
and analyzed by FlowJo (version 7.2.5; TreeStar, Ashland, OR)
and SPICE (version 4.1.6). The expression of CD107a, IFNc, IL-
2, MIP-1b, TNFa and T cell surface markers was quantified
separately and in combination.
Statistical analysis
Statistical analyses were carried out to test three specific
hypotheses: (a) PBMC and CD8+ T cell responses to HIV-1
peptides are stronger in the presence than in the absence of DC;
(b) CD8+ T responses to HIV-1 peptides exceed PBMC responses
DC Enhance Anti-HIV T Cells
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e12936
both in the presence and in the absence of DC; and (c) relative
changes in the level of response to HIV-1 peptides is highly
correlated between CD8+ T cells and PBMC both in the presence
and the absence of DC. The first two hypotheses were tested using
the binomial sign test. In each case, the peptide data was
transformed into a binary variable and tested against the null
hypothesis (H0 = 0.5) using a one-sided alternative. For the first
two hypotheses, we also calculated mean ratios and 95%
confidence intervals in order to provide a better sense of the size
of the comparative responses. For the third hypothesis, we ranked
the size of the response observed to each of the HIV-1 peptides by
PBMC and CD8+ T cells both in the presence and the absence of
DC. Under both of the latter conditions (presence or absence of
DC), we calculated Spearman rank order correlations between the
PBMC and CD8+ T cell responses and the statistical significance
(p-value) of each correlation. We used the Scheffe multiple
comparison test and chi-square test for analysis of the polyfunc-
tional T cell results.
Results
Enhanced breadth of IFNc production by CD8+ T cells
stimulated by DC loaded with peptide pools
representing the HIV-1 proteome
We first examined the effects of DC loaded with a library of
overlapping 15mer peptides spanning the HIV-1 proteome
arranged into 29 pools of 19–32 peptides each on T cell
reactivity in HIV-1 infected persons on ART. We have
previously shown that CD40L-matured DC loaded with pools
of #32 HIV-1 peptides are optimal for stimulation of CD8+ T
cell responses [24]. In the present study we found that peptide-
loaded, CD40L-treated DC induced higher levels of peptide-
specific, IFNc production across the HIV-1 proteome in PBMC
compared to that stimulated by the HIV-1 peptide pools without
DC (P,0.05) (Fig. 1 A1, B1, C1). No IFNc responses were
observed using peptide-stimulated PBMC or CD8+ T cells from 3
HIV-1 seronegative, uninfected persons, with or without DC
(data not shown). Furthermore, using purified CD8+ T cells as
responders, we confirmed that the broad reactivity induced by
the peptide-loaded DC was mediated by CD8+ T cells, as there
was a correlation between the total response of the purified CD8+
T cells and the PBMC to the HIV-1 peptide pools (r = 0.845,
P,0.001) (Fig. 1 A2, B2, C2). This enhanced breadth was noted
by a 6.6 mean ratio increase (CI 4.53-8.67, P,0.001) in the total
CD8+ T cell positive response to peptides with DC compared to
stimulation with peptides without DC. Finally, using peptide-
loaded DC, we detected CD8+ T cell responses to 21/29, 22/29
and 7/29 peptide pools in subjects 1, 6 and 7, respectively. These
included reactivity to peptides within each HIV-1 protein except
Vpu for subjects 1 and 6, and to peptides within Env, Gag, Pol
and Vif for subject 7. Finally, the overall magnitude of the IFNc
responses was greater in purified CD8+ T cells than in the
PBMC, with a mean ratio of the CD8+ T cell response to the
PBMC response of 1.20 (CI 0.98-1.42, P,0.001) for the peptides
in the absence of DC, and 1.57 (CI 1.35-1.80, P,0.001) in the
presence of DC.
These results indicate that the IFNc production in response to
DC loaded with HIV-1 15mer peptides was produced mainly by
CD8+ T cells in the PBMC cultures. These immune responses
were of significantly greater magnitude and breadth across the
whole HIV-1 proteome (except Vpu) compared to those induced
by conventional stimulation with peptides without DC in HIV-1
infected persons on ART.
Enhanced breadth of T cell IFNc production stimulated
by DC loaded with single HIV-1 Nef 15-mer peptides
We next focused on HIV-1 specific IFNc production in
response to CD40L-treated DC that were loaded with single
peptides spanning 49 consecutive HIV-1 Nef 15mers overlapping
by 11 amino acids in HIV-1 infected persons on ART. As
expected, the number of positive responses to Nef varied among
these genetically disparate study subjects (Fig. 2). Of the 343
possible T cell responses to the 49 Nef peptides among the 7
subjects, there were 74 (21.6%) positive T cell responses to DC
loaded with the Nef peptides compared to only 5 (1.5%) positive
responses to Nef peptides without DC (P,0.001). There were 7
(2%) common responses to peptides with and without DC. DC
enhanced the number of Nef peptide-responding T cells by an
average of 23.4 fold as compared to T cells stimulated directly with
the peptides (no DC) (P,0.001 for unadjusted for background
responses, p = 0.023 for adjusted values) (data not shown).
Moreover, the positive responses were greater with DC loaded
with Nef peptides than with Nef peptides without DC (P,0.001).
The enhanced T cell responses to Nef were HIV-1 specific,
reproducible in 2 subjects re-evaluated (P = ns) and not associated
with CD4+ T cell counts or viral load in the 7 HIV-1 infected
subjects (data not shown).
Based on MHC class I alleles of the 7 subjects, we next
determined the known and potential Nef epitopes associated with
the T cell responses. There were 19 known Nef epitopes matched
for the MHC class I alleles of the 7 subjects within the 42 Nef
15mers that induced positive responses (Table S2). Of these, the
broadest IFN-c responses to the Nef 15mer peptides were observed
for subject 7 and the most restricted for subject 5 (Fig. 2). There
were also responses to the 15mer Nef peptides that were not
associated with a known epitope matched for the study subjects’
MHC class I alleles for 24/42 (57%) of the reactive Nef peptides.
Of the 37 total responses to these 24 peptides, 35 (94.6%) only
occurred in response to peptide with DC, whereas 2 (5.4%) were in
response to peptide with and without DC. There were also over 60
potential new MHC class I-restricted epitopes identified by their
binding motifs within the positive Nef 15mer peptides (data not
shown).
Taken together, these results show that DC from HIV-1
infected subjects on ART can process 15mer peptides for
stimulation of responses against a broad range of known and
potential Nef epitope in greater magnitude and breadth compared
to that stimulated by these Nef peptides without DC.
Novel HLA B*2703 Nef epitope revealed by stimulation
with peptide-loaded DC
To verify recognition of novel MHC class I Nef epitopes
revealed by DC, we mapped a minimal epitope within the
15mer Nef73–87 (QVPLRPMTYKAAVDL) peptide. We found
that stimulation with peptide-loaded DC, but not with peptide
without DC, resulted in positive IFN-c responses in PBMC from
3 HIV-1 infected subjects who shared HLA B*2703 (peptide 19,
Table S2 and subjects 4, 6 and 7, Fig. 2). We then focused on the
internal 9mer LRPMTYKAA that was predicted to be
restricted by HLA B*2703. Using cells derived from subject 6,
DC loaded with Nef76–84 (LRPMTYKAA) stimulated the
highest levels of IFNc compared to N and C terminal extended
and truncated peptides, in a concentration-dependent manner
(Fig. 3, DC vs No DC). We confirmed the MHC class I
restriction of this response using BLCL as APC that were MHC
class I-matched only for HLA B*2703 (Fig. 3, BLCL-HLA
B*2703).
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Figure 1. Single cell IFN gamma production by purified CD8+ T cells compared to PBMC in response to DC loaded with peptides
spanning the HIV-1 proteome. A library of HIV-1 15mer peptides overlapping by 11 aa that spanned the HIV-1 proteome was arranged into 29
pools of 19–32 peptides per pool. HIV-1-specific reactivity in PBMC (A1, B1 and C1) and purified CD8+ T cells (A2, B2 and C2) was assessed in 3 HIV-1
infected persons (subjects 1, 6 and 7) in response to CD40L-matured DC that were loaded with each of the peptide pools. Mean + SE in triplicate
cultures. The horizontal lines above the abscissa delineate the positive cutoff for each subject’s T cell response.
doi:10.1371/journal.pone.0012936.g001
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To assess the effects of DC on the breadth of the polyfunctional
CD8+ T cell response, we studied Nef73–87 using multiparameter
flow cytometry of PBMC stimulated with CD40L-matured DC
loaded with peptide [24]. 3 of the 4 overlapping, 15mer peptides
containing portions of the optimal epitope (Nef76–84) detected by
the ELISPOT assay, i.e., Nef69–83, Nef73–87 and Nef77–91, induced
the greatest polyfunctional CD8+ T cell responses when presented
without DC (P,0.01 compared to N flanking Nef65–79) (Fig. 4A,
no DC). This included CD8+ T cells producing all 5 of the
immune mediators, i.e., CD107a, IFNc, IL-2, MIP-1b and TNFa
(P,0.01). With DC, the Nef69–83 and Nef73–8715mers induced the
greatest polyfunctional CD8+ T cell responses (P,0.05 compared
to Nef65–79 and Nef77–91) (Fig. 4A, DC). Among the 8-10mer
peptides from this region presented without DC, the greatest
polyfunctional response was induced by Nef76–84. This peptide
without DC induced a trend towards a higher number of
polyfunctional CD8+ T cells producing 2-to-4 immune mediators,
i.e., IFNc and IL-2, as well as MIP-1b and TNFa, compared to
the 4 N and C terminal extended and truncated peptides (P = 0.07)
(Fig. 4B, no DC). In contrast to stimulation without DC, there was
no distinct polyfunctional CD8+ T cell response to DC loaded with
each of the 5 8-10mer variants (P = ns) (Fig. 4B, DC). Mostly
monofunctional and dual polyfunctional T cells were stimulated
by these peptides with DC.
These results show that DC revealed a new, HLA B*2703
epitope, Nef76–84, by a conventional ELISPOT in individuals on
ART that was unrecognized using direct stimulation of PBMC
with peptide alone. Monofunctional and polyfunctional ICS
responses supported that these overlapping Nef 15mers contained
a dominant CD8+ T cell epitope. However, a range of less
definitive, CD8+ T cell activity was noted against Nef76–84 as well
as to the N and C terminal variants, with and without DC.
Enhanced breadth of T cell IFNc production stimulated
by DC loaded with single HIV-1 Gag 15-mer peptides
We next determined HIV-1 specific IFNc production in
response to CD40L-treated DC that were loaded with single
peptides spanning HIV-1 Gag (122 consecutive 15mers overlap-
ping by 11 amino acids) in HIV-1 infected persons on ART.
Overall, there were responses to 80 of the 122 peptides by PBMC
from the 7 subjects presented with or without DC (Fig. 5). Subjects
1, 2 and 7 had the broadest responses, i.e., 33, 35 and 33
responses, respectively. In contrast, only 7 peptides induced T cell
responses from subject 5.
Of the total of 854 possible responses to the 122 Gag peptides
among the 7 subjects, there were 114 (13.3%) responses to DC
loaded with Gag peptides compared to only 14 (1.6%) responses to
peptides without DC (P,0.001). There were 24 (2.8%) common
Figure 2. Enhanced single cell IFN gamma production stimulated by DC loaded with HIV-1 Nef 15mer peptides. CD40L-matured DC
were loaded with single HIV-1 15-mer peptides spanning Nef and compared to peptides without DC for stimulation of HIV-1 specific IFN gamma
production in 7 HIV-1 infected subjects on ART. The horizontal lines above the abscissa delineate the positive cutoff for each subject’s T cell response.
doi:10.1371/journal.pone.0012936.g002
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responses to peptides with and without DC. Higher magnitude
responses were observed to DC loaded with peptides compared to
peptides without DC (P,0.001). DC enhanced the number of Gag
peptide-responding T cells by an average of 8.5 fold (P,0.001).
Enhanced T cell responses to Gag were not associated with
CD4+ T cell counts or viral load in the 7 infected subjects (data not
shown). Repeat testing of different blood samples from 2 of these
subjects resulted in IFNc production comparable to the previous
responses (P = ns; data not shown). IFNc production was HIV-1
immune specific, as there was little or no IFNc production induced
by the Gag peptides with or without DC in 4 HIV-1 negative
controls (data not shown).
We assessed these data for known and potential new Gag
epitopes based on MHC class I alleles of the 7 subjects. Results in
Table S3 show that there were 57 known Gag epitopes matched
for the MHC class I alleles of the 7 subjects within the 80 Gag
15mers that induced positive responses. Known MHC class I
epitopes mostly clustered within Gag p175–31, p1773–103, p245–27,
p2457–95, p24117–179 and p24205–227. The breadth of responses
varied across subjects (Fig. 5; Table S3). 44 (55%) of the 80
reactive Gag peptides were not associated with a known epitope
matched for the subjects’ MHC class I alleles, corresponding to a
total of 68 responses: 60 (88.2%) were in response to peptide with
DC, 5 (7.4%) were in response to peptide alone, and 3 (4.4%) were
in response to both. Based on prediction models for peptide
binding to the various MHC class I alleles of these 7 subjects, there
were over 200 potential new Gag epitopes identified within the 80
positive Gag 15mer peptides (data not shown).
These results together indicate that in persons on ART, DC
reveal significantly more T cell responses to Gag epitopes than did
conventional stimulation with peptide alone.
Novel HLA B*5101 Gag epitope within p17 revealed by
stimulation with peptide-loaded DC
We determined whether stimulation of PBMC with peptide-
loaded DC revealed novel MHC class I epitopes for Gag. We
first focused on Gag p1717–31 (EKIRLRPGGKKKYKL) that
elicited positive IFNc responses with DC in 4 of 7 subjects, and its
C terminal overlapping peptide p1721–35 (LRPGGKKKYKL-
KHIV), which was positive in 2 of 7 subjects using DC (peptides 5
and 6, Fig. 5, Table S3). A greater IFN-c response was detected to
DC loaded with p1717–31 or p1721–35 than to peptides without DC
in HLA B*5101 positive subject 2 (i.e., 1,585 vs. 9 SFC, and 985
vs. 69 SFC, respectively; P,0.01). Analysis using the HLA Binding
Motif Scanner [19] suggested that p1723–31 (PGGKKKYKL) was
a potential new epitope for HLA B*5101. ELISPOT results for the
predicted epitope showed that the 10mer sequence p1722–31
(RPGGKKKYKL) stimulated IFN-c production without DC in a
concentration-dependent manner (Fig. 6A, No DC) at levels
approximately 2.5-fold higher than without DC. The other
Figure 3. Stimulation of T cells with peptide-loaded DC reveals a novel HLA B*2703 restricted, Nef epitope determined by single
cell IFN gamma production. Using PBMC from HIV-1 infected subject 6 and in silico predictions, a new HLA B*2703-restricted epitope Nef76–84
(LRPMTYKAA) was revealed within 15mer Nef73–87. The PBMC were stimulated with different concentrations of N and C terminal extensions and
truncations of this peptide without DC (No DC), with DC (DC), and with BLCL matched at only one MHC class I allele (B*2703) to confirm the HLA
restriction of the responses.
doi:10.1371/journal.pone.0012936.g003
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peptide variants also induced concentration-dependent IFN-c
production at lower levels than p1722–31 when presented by DC
(Fig. 6A, DC). We confirmed that the p1722–31 10mer was HLA
B*5101-associated by demonstrating optimal, concentration-de-
pendent reactivity using BLCL matched only for this MHC class I
allele (Fig. 6A; BLCL- B*5101 matched).
The overlapping 15mer peptides and the 8-10mer peptides
stimulated polyfunctional CD8+ T cell reactivity in subject 2
detected by multicolor flow cytometry analysis of CD107a, IFNc,
IL-2, MIP-1b and TNFa. Without DC, higher numbers of
monofunctional and polyfunctional CD8+ T cells expressed various
combinations of these immune mediators in response to the 15mer
peptides p1717–31 and p1721–35 that contained the ELISPOT-
optimal p1722–31 10mer, compared to the N and C terminal
flanking 15mer peptides p1713–27 and p1725–39 (P,0.001) (Fig. 7A:
no DC). Stimulation with peptide-loaded DC induced monofunc-
tional responses for CD107a, IFNc and IL-2, and combinations of
2, 3 and 4 polyfunctional responses in CD8+ T cells to all 4 of the
15mers (P,0.03 compared to no DC) (Fig. 7A: DC). Of the 8-
10mer peptides, in the absence of DC, most monofunctional and
polyfunctional responses were induced by the 10mer p1722–31,
although there was no significant difference compared to the other 4
peptides (P = ns) (Fig. 7B: no DC). Using peptide-loaded DC, strong
monofunctional and polyfunctional CD8+ T cell responses of 2-to-4
immune mediators were observed to all 5 8-10mer peptide variants
(P = 0.04 compared to no DC) (Fig. 7B: DC).
Figure 4. Induction of polyfunctional CD8+ T cells by DC loaded with a novel HLA B*2703 Nef epitope. Production of 5 immune
mediators by CD8+ T cells from HIV-1 infected subject 6 was assessed in response to 4 overlapping 15mer peptides spanning Nef65–91(i.e., Nef65–79,
Nef69–83, Nef73–87, and Nef77–91), with and without DC (Fig. 4A), and the in silico predicted optimal 9mer epitope Nef76–84 (LRPMTYKAA) and 4 N and C
terminal variants with and without DC (Fig. 4B). The 5 color pie charts show the relative proportions of immune mediators produced in combinations
of 1 to 5 per CD8+ T cell, and the color bar graphs represent the percentage of T cells responding to each individual 15mer (Fig. 4A) or 8-10mer
peptides (Fig. 4B). The horizontal bars with different colors represent the percentage of CD8+ T cells producing one of the 5 immune mediators in
response to the peptides. Each dot represents production of CD107a, IFN gamma, IL-2, MIP-1 beta or TNF alpha.
doi:10.1371/journal.pone.0012936.g004
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Thus, using DC and single cell IFN-c production, we identified
Gag p1722–31 as a novel, optimal 10mer epitope restricted by HLA
B*5101. Polyfunctional CD8+ T cell responses induced by the
15mer peptide-loaded DC supported this peptide as the optimal
epitope, but were less discriminatory among the 8-10mer, N and C
terminal variants presented with or without DC.
Novel HLA A*0101 and B*5101 Gag epitopes within p24
revealed by stimulation with peptide-loaded DC
A cluster of positive responses resulted from stimulation with
peptides 74–76 from the p24 region of Gag, with 4/7 subjects
responding to p24161–175 (FRDYVDRFYKTLRAE), 5/7 to
p24165–179 (VDRFYKTLRAEQASQ) and 4/7 to p24169–183
(YKTLRAEQASQEVKN), whereas there were no responses to
either the N or C terminal flanking 15mers (Fig. 5; Table S3). 12 of
13 positive IFN-c responses were detected only following
stimulation with DC loaded peptides. HLA Binding Motif Scanner
[19] predicted that p24161–169 (FRDYVDRFY) was a potential
new epitope restricted by HLA A*0101, and p24173–181 (RAE-
QASQEV) for HLA B*5101.
Testing of N and C terminal, 8-10mer extensions and trunca-
tions of p24161–169 showed that there was little or no IFN-c
production induced at any peptide concentration without DC in
subject 2 (Fig. 6B, no DC). With DC, however, concentration-
dependent IFNc responses were induced to 3 of these 5 peptides,
with the greatest response to the predicted optimal 9mer p24161–169
for HLA A*0101 (Fig. 6B, DC). Although no distinct, concentra-
tion-dependent reactivity was observed, the greatest responses were
induced by the 9mer p24161–169 and the 8mer p24161–168 (Fig. 6B,
BLCL-A*0101 matched).
Concentration-dependent IFNc ELISPOT responses were max-
imal with the 10mer p24173–182 (RAEQASQEVK), one aa longer
than the predicted, optimal HLA B*5101 epitope p24173–181 (Fig. 6C,
No DC and DC). The response was also greatest to p24173–182
presented by BLCL matched only for MHC class I at HLA B*5101
(Fig. 6C, BLCL - B*5101).
Among the 3 overlapping 15mer peptides, optimal monofunction-
al and polyfunctional CD8+ T cell responses were elicited only by
p24165–179 in the absence of DC (P = 0.02 compared to p24161–175
and p24169–183) (Fig. 8A, no DC), including cells expressing various
combinations of CD107a, IFNc, IL-2, MIP-1b and TNFa. In
contrast, with DC, a broad array of monofunctional and polyfunc-
tional responses were induced in CD8+ T cells by p24165–179 (P = 0.01
compared to p24161–175) and p24169–183 (P = 0.07 compared to
p24161–175) (Fig. 8A, DC).
Figure 5. Enhanced single cell IFN gamma production stimulated by DC loaded with HIV-1 Gag 15mer peptides. CD40L-matured DC
were loaded with single 15mer peptides spanning Gag p55 and compared to these peptides without DC for stimulation of HIV-1 specific, IFN gamma
production in 7 HIV-1 infected subjects on ART. The horizontal lines above the abscissa delineate the positive cutoff for each subject’s T cell response.
doi:10.1371/journal.pone.0012936.g005
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Without DC, the p24161–169 (FRDYVDRFY) peptide and its 8-
10mer peptide variants showed no distinct, polyfunctional CD8+ T
cell responses (P = ns) (Fig. 8B, no DC). Rather, it induced
predominantly monofunctional responses for CD107a, IL-2 and
TNFa, and only two polyfunctional responses (IFNc + MIP-1b +
TNFa and IFNc + TNFa) (P = ns) (Fig. 8B, no DC). With DC, all
5 peptides induced CD107a + TNFa, CD107a + MIP-1b and
CD107a + IL-2 (P,0.02 compared to no DC) (Fig. 8B, DC).
Predominantly monofunctional and some dual polyfunctional
CD8+ T cell responses were induced by the 5 peptides without DC
derived from the putative optimal 9mer p24173–181 peptide, with
no distinct response to a particular peptide (P = ns) (Fig. 8C, No
DC). Likewise, a broad array of polyfunctional responses to these
peptides was detected using DC as APC (P,0.02 compared to No
DC) (Fig. 8C, DC). In particular, cells producing CD107a + TNFa
and CD107a + IL-2 were induced by all 5 peptides.
Taken together, our data indicate that within this cluster of 3
overlapping Gag p24 15mers, stimulation with peptide-loaded DC
revealed a novel HLA A*0101 9mer epitope p24161–169, and a
novel HLA B*5101 10mer epitope p24173–182. N and C terminal
variants of these optimal peptides were able to induce appreciable
levels of IFN-c detected by ELISPOT assay only when using DC
as APC. There was no clear immunodominance of these 2 Gag
p24 epitopes compared to their 8-10mer variants detected by
monofunctional or polyfunctional CD8+ T cell responses when
presented with or without DC.
Discussion
Control of HIV-1 infection has been related to the magnitude
and breadth of HIV-1 CD8+ T memory responses, particularly
against Gag [1]. While it has been well established that DC are
required for priming of naı¨ve CD8+ T cells [14], it has only
recently been shown that DC are also necessary for optimal
activation and expansion of memory CD8+ T cells to non-HIV-1
viral infections [14,15,16,17,18]. We therefore hypothesized that
DC could enhance memory T cell reactivity to HIV-1. In support
of this hypothesis, we show here that DC loaded with HIV-1
peptides induced the greatest breadth of anti-HIV-1 recall
(memory) CD8+ T cell reactivity in persons on ART. The IFNc
response induced by peptide loaded DC was mediated by CD8+ T
cells, with purified CD8+ T cells exhibiting an enhanced
magnitude and breadth of IFNc responses relative to PBMC.
The 15mer peptides targeted by CD8+ T cells were similar to
those targeted by PBMC, but included a broader array of peptides
across the proteome of HIV-1. CD8+ T cell responses were noted
Figure 6. Stimulation of T cells with peptide-loaded DC reveals 3 novel HLA Gag HLA A*0101 and B*5101 epitopes determined by
single cell IFN gamma production. Using PBMC from HIV-1 infected subject 2, 3 novel epitopes were identified within Gag 15mer peptides
spanning p1717–35 and p24161–183. Concentration-dependent, single cell IFN gamma production was optimal to peptides with DC for the 10-mer
p1722–31 (RPGGKKKYKL) for HLA B*5101 (Fig. 6A, DC vs. No DC), 9mer p24161–169 (FRDYVDRFY) for HLA A*0101 (Fig. 6B, DC vs. Non DC) and 9mer
p24173–181 (RAEQASQEV) for HLA B*5101 (Fig. 6C, DC vs. No DC). The HLA restriction of the responses was confirmed by stimulation of the PBMC with
peptide-loaded BLCL matched at only one MHC class I allele shown (BLCL, Figs. 6A–C).
doi:10.1371/journal.pone.0012936.g006
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to DC loaded with 15mer peptides within all 9 HIV-1 proteins
except Vpu. Confirming evidence that CD8+ T cells were the
predominant responders to HIV-1 peptides was induction of
polyfunctional immune mediator reactivity in CD8+ T cells to
both Gag and Nef peptides.
Focusing on Nef and Gag specificities, we found that T cells
responded to clusters of overlapping 15mer Nef and Gag peptides
that contained known, immunodominant epitopes matched to the
subjects’ MHC class I alleles. Notably, T cell reactivity was
induced to 22% of these overlapping 49 Nef peptides by DC
compared to only 4% of Nef peptides without DC. Furthermore,
the magnitude of the anti-Nef responses was significantly greater
for peptides with DC compared to peptides without DC. Similar to
Nef, positive T cell responses to Gag 15mers containing known
MHC class I epitopes were clustered in well documented,
immunodominant regions of the protein that matched the MHC
class I alleles of our study subjects. DC revealed T cell responses to
16% of these overlapping 122 Gag peptides compared to only 4%
of Gag peptides without DC. The magnitude of the anti-Gag
responses was also significantly greater for Gag peptides presented
by DC compared to peptides without DC.
That autologous, mature DC significantly enhance the breadth and
magnitude of CD8+ T cell responses to immunodominant epitopes of
Nef and Gag has important implications for assessment of T cell
immunity in HIV-1 infection. Much of this research relies heavily on
use of overlapping 15mer peptides in PBMC without taking into
account the role of professional APC [3,25,26,27,28,29,30]. 15mers
require processing and presentation by APC, including professional
APC, i.e., monocytes, B lymphocytes and myeloid DC, as well as NK
and T cells [31,32,33,34,35,36]. While it is also possible that this IFN-c
Figure 7. Induction of polyfunctional CD8+ T cells by DC loaded with a novel HLA B*5101 Gag p17 epitope. Production of 5 immune
mediators by CD8+ T cells from HIV-1 infected subject 2 was assessed in response to 4 overlapping 15mer peptides spanning p1717–35 (i.e., p1713–27,
p1717–31, p1721–35, and p1725–39), with and without DC (Fig. 7A), and the in silico predicted, optimal 9mer p1723–31 (PGGKKKYKL) for HLA B*5101 and 4
N and C terminal variants with and without DC (Fig. 7B). The details of the graphs are described in Fig. 4.
doi:10.1371/journal.pone.0012936.g007
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production to 15mers represents MHC class II restricted, CD4+ T cell
reactivity [37,38,39], CD8+ T cells were the predominant responders
in our study. Our finding implies that the conventional assessment of
single cell, IFN-c responses to libraries of overlapping HIV-1 peptides
without DC is potentially missing a significant number of epitopes in
persons on ART.
We noted reactivity to 15mer peptides with no previously
reported epitope matched for the study subjects’ MHC class I
alleles for 52% of the reactive Nef peptides and 55% of the
reactive Gag peptides. Most of this reactivity was in response to
peptides with DC, i.e., T cells specific for 86% of the reactive Nef
peptides and 75% of the reactive Gag peptides were only
Figure 8. Induction of polyfunctional CD8+ T cells by DC loaded with 2 novel HLA A*0101 and B*5101 Gag p24 epitopes. Production
of 5 immune mediators by CD8+ T cells from HIV-1 infected subject 2 was assessed in response to 3 overlapping 15mer peptides spanning p24161–183
(i.e., p24293–307, p24297–311, and p24301–315), with and without DC (Fig. 8A) and the in silico predicted, optimal 9mers and 4 N and C terminal variants of
p24161–169 (FRDYVDRFY) for HLA A*0101 (Fig. 8B) and p24173–181 (RAEQASQEV) for HLA B*5101 (Fig. 8C), with and without DC. The details of the
graphs are described in Fig. 4.
doi:10.1371/journal.pone.0012936.g008
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activated by peptide-loaded DC. Analysis of these peptide
sequences by predicted binding to their MHC class I motif
[19,20,21] indicated that many of the peptides contained
potential epitopes for the MHC class I alleles of our study
subjects. It should be noted that our functional assays could be
detecting MHC class I-restricted T cell epitopes on alternative
alleles [40]. Furthermore, computational models for predicting
MHC-peptide binding are not highly efficient at delineating T
cell epitopes [41,42,43]. For example, a recent study of influenza
A virus [44] showed that only 8% of over 100 viral peptides
predicted to bind to MHC class I molecules simulated memory T
cell responses in vitro using PBMC from normal adults who
presumably had been previously exposed to influenza A virus.
Indeed, T cell reactive, viral peptides do not always conform to
their putative MHC class I binding motif [45]. It is also notable
that DC have not been used as APC in most viral epitope
discovery studies [18,46].
An extensive analysis of a subset of these putative Nef and Gag
epitopes indicated that DC indeed revealed novel epitopes for
Nef and Gag. Based on single cell IFN-c production induced by
the 15mer Nef73–87 with DC, and the predicted binding motif of
HLA B*2703, we defined a novel HLA B*2703 epitope, Nef76–84
(LRPMTYKAA). This new HLA B*2703 Nef epitope is found in
34% of circulating HIV-1 subtype B sequences, while the most
common peptide is LRPMTYKgA found in 42% of circulating
sequences (based on a dataset of 1184 subtype sequences). This is
a variable peptide region since 77 additional peptides were
identified in the 1184 circulating sequences but 73 of them were
found in less than 1% of sequences. Similarly, using DC we found
3 novel epitopes within Gag that would have been missed using
peptide stimulation alone. The 10mer HLA B*5101 epitope for
p17 (p1722–31; RPGGKKKYKL) is found in 24% of circulating
sequences, while RPGGKKKYrL is found in 27% of sequences.
The Gag p24161–169 peptide RAEQASQEVK (HLA A*0101
restricted) is the consensus in 49% of circulating HIV-1
sequences, whereas p24173–182 FRDYVDRFY (HLA B*5101
restricted) is extremely conserved, found in 99.5% of HIV-1
sequences.
We observed that the 15mer overlapping peptides encompass-
ing the 4 novel Nef and Gag epitopes, as well as the 8-10mer
epitope variants within these 15mers, induced monofunctional
CD8+ T cell reactivity for CD107a, IFNc, IL-2, MIP-1b, and
TNFa, and various polyfunctional combinations of these immune
mediators. In particular, the novel Gag peptides presented by DC
induced greater levels of polyfunctional CD8+ T cells than
peptides without DC. However, with or without DC, polyfunc-
tional T cell responses were less discriminatory for optimal epitope
specificity than single cell production of IFN-c by ELISPOT assay.
We have recently noted a similar, limited discrimination by
polyfunctional analysis of novel T cell epitopes of human
herpesvirus 8 presented by DC [47].
There are many factors of mature DC that could relate to their
enhancing afferent T cell responses to HIV-1 epitopes. In primary
CD8+ T cell responses, the majority of immunodominance is
based on the affinity of the peptide for its MHC class I allele on
APC, forming a stable number of complexes to activate naive T
cells [43,48]. This is also important in stimulation of memory T
cells, which are in greater quantity and have a lower threshold for
activation than naı¨ve CD8+ T cells. However, it is not clear how
closely measures of binding of soluble peptides to MHC class I
molecules by in vitro affinity assays reflect peptide-MHC binding
in DC. Moreover, an increased antigen storage capacity of DC has
been linked to their ability to activate T cells by facilitating a
continuous supply of MHC class I ligands [49]. DC also enhance
the duration of peptide-MHC class I – T cell interactions that are
essential for inducing maximum CTL activity [50]. Finally,
expression of T cell co-receptors and polarizing, immunomodu-
latory cytokines such as IL-12 are central to the ability of DC to
stimulate antigen-specific CD8+ T cells [51,52], including HIV-1
antigens [53].
Activation of CD8+ T cells by DC is also related to the relative
expression of T cell receptor and CD8 molecules on memory T
cells [54,55,56]. The epitope recognition in our study likely
involves functional avidity of the antigen-responding T cells, i.e.,
their capacity to respond to various levels of peptide-MHC class I
complexes on the DC [57]. We used a relatively high
concentration of peptide with the DC, which could result in
preferential stimulation of high avidity, HIV-1 specific T cells [58],
as well as cross-reactivity by less avid, non-HIV-1 specific T cells
[59]. To limit this effect, we treated the DC with peptide for only
2 h, followed by washing out excess peptide prior to stimulation of
the T cells. We also found T cell reactivity to DC loaded with low
concentrations of the Nef and Gag peptide epitopes and their
variants.
In conclusion, our findings have important implications for T
cell immune control of HIV-1 infection. Previously reported, low
memory recall, CD8+ T cell responses to HIV-1 epitopes in
subjects who have suppressed HIV-1 infection on ART may be
misleading. Clearly, the present results indicate that mature DC
reveal a broad spectrum of T cell epitopes recognized by CD8+ T
cells in persons on ART with suppressed viral load that are not
detectable by conventional stimulation of PBMC with peptide
alone. These include novel, MHC class I restricted, HIV-1
epitopes that induce monofunctional and polyfunctional T cells
producing up to 5 immune mediators that have been linked to
control of HIV-1. This suggests that DC could be potent inducers
of anti-HIV-1 T cell immunity as an immunotherapy for HIV-1
infected persons on ART.
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